Your Guide to the Latest CRISPR Tools: What’s New and What’s Next in Gene Editing
2024-09-11
What are the different types of CRISPR-Cas9?
The CRISPR-Cas9 system has revolutionized the field of genetic engineering, offering unprecedented precision in gene editing. As the technology evolves, so do its applications. Let's explore the different types of CRISPR-Cas9 that are shaping the future of gene editing.
Classical Cas9 Editing
The classical Cas9, often referred to as CRISPR-Cas9, is a powerful gene-editing tool that functions like molecular scissors, precisely cutting specific DNA sequences. Guided by RNA (gRNA), Cas9 identifies the target DNA sequence and makes a precise cut, enabling gene disruption, deletion, or insertion.
Despite its promise as a therapeutic tool, CRISPR-Cas9 had not been used clinically until the approval of CASGEVY™. This therapy was designed to transform the abnormal β-globin subunits in hemoglobin S found in blood stem cells into their fetal hemoglobin F (HbF) counterparts. CASGEVY™ achieves this by deactivating BCL11A, a transcription factor that represses the expression of γ-globin and HbF in erythroid cells after birth. The CRISPR-Cas9-edited stem cells are then infused back into the patient in a single-dose treatment, with the goal of enabling them to engraft in the bone marrow. [1, 2]
Before the modified cells are reintroduced, the patient must undergo myeloablative conditioning (high-dose chemotherapy), which eliminates the affected cells from the bone marrow to allow the modified CASGEVY™-treated cells to take their place. If successful, the engrafted cells will boost HbF production, the primary oxygen-carrying protein in fetal red blood cells. This increased HbF production is expected to raise circulating HbF levels and stop the sickling of red blood cells in patients with sickle cell disease.
Base Editing
Base editing is an advanced genome-editing technique that enables precise single-nucleotide changes in DNA without inducing double-strand breaks (DSBs) or relying on homology-directed repair (HDR). [3] By fusing a Cas9 nickase to a deaminase [4], base editors (BEs) can target specific genomic sites to convert cytosine to thymine (C to T) or adenine to guanine (A to G), potentially correcting up to 60% of pathogenic point mutations. While base editing offers significant advantages over traditional CRISPR/Cas9 methods, particularly in addressing genetic diseases, it has limitations, such as difficulty targeting certain mutations like deletions and multi-nucleotide changes. To address these challenges, new tools like prime editing and CRISPR-integrases are being developed.
Prime Editing
Prime editing is a groundbreaking genome-editing technology that offers enhanced precision and versatility compared to traditional CRISPR-Cas9 methods. [5] Developed in 2019, this system enables the introduction of specific mutations and small insertions without inducing DSBs, thereby minimizing the risk of errors and unintended mutations. It operates by fusing a Cas9 nickase with a reverse transcriptase, guided by a prime editing gRNA (pegRNA) that directs and templates the desired DNA modification. Additionally, by using paired pegRNAs, prime editing can achieve larger insertions (up to 110 bp) [6] or generate significant genomic deletions, though delivering larger genetic cassettes remains a challenge for this method.
In summary, the evolution of CRISPR from a microbial immune system to a transformative genome editing tool illustrates the power of basic scientific discovery to revolutionize biotechnology and potentially reshape medicine in the future.
Related Products:
- Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2021 Jan 21;384(3):252-260.
- US Food and Drug Administration. FDA News Release. FDA approves first gene therapies to treat patients with sickle cell disease.
- Rees HA, Minella AC, Burnett CA, Komor AC, Gaudelli NM. CRISPR-derived genome editing therapies: Progress from bench to bedside. Mol Ther. 2021 Nov 3;29(11):3125-3139.
- Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038/nature24644. Epub 2017 Oct 25. Erratum in: Nature. 2018 Jul;559(7714):E8.
- Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019 Dec;576(7785):149-157.
- Anzalone AV, Gao XD, Podracky CJ, Nelson AT, Koblan LW, Raguram A, Levy JM, Mercer JAM, Liu DR. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol. 2022 May;40(5):731-740